Search

everythinglearnresearchcommunity

for

Search:↓

GeneTherica is discussed as a source for RU58841, with ordering possible via WhatsApp. The conversation focuses on the legitimacy of this supplier for hair loss treatment.

VDPHL-01 is essentially a slow-release oral minoxidil, which is already known to work for hair growth. The formulation includes other ingredients like Medrogestone, Valproic acid, Setipiprant, and Cetirizine, but their effectiveness and necessity are questioned.

A drug that regrows body parts, but not hair, sparking debate on hair loss treatments. Discussions include the use of finasteride, dutasteride, and the potential for new methods to restore hair.

PP405 is a potential hair loss treatment, but its safety and effectiveness are uncertain. Users advise caution and suggest waiting for more data before purchasing unverified versions.

Stemoxydine is a hair loss treatment discussed in a forum. Its effectiveness is questioned by users.

User discusses tight scalp causing hair loss and suggests treatments like scalp massages, PRP, saw palmetto, and eucapil. They share their experience with saw palmetto and eucapil and consider adding PRP and scalp massages for better results.

Dr. Tsuji is giving online lectures about hair multiplication trials. Users express hope for a cure, but some are skeptical about its timeline.

PP405 is a potential hair loss treatment showing promising early results, with hopes for market release by 2028, but skepticism remains due to inconclusive data and past disappointments with similar products. Current treatments like Minoxidil and Finasteride have side effects, leading some to anticipate PP405 as a safer alternative, though its effectiveness compared to placebo is debated.

The user had four DHI hair transplants from 2021 to 2025 and is concerned about the lack of hair thickening despite using treatments like finasteride and minoxidil. They are seeking advice on why these efforts aren't working.

A user is planning to use mesotherapy with 0.025% dutasteride for hair maintenance due to intolerance to finasteride. They seek clinics in Northern Germany, Sweden, or nearby countries for dutasteride scalp injections.

The user experienced severe side effects when using topical Dutasteride and RU58841 together and is considering using them at different times of the day. They are seeking advice on whether this approach might reduce side effects.

An 18-year-old with diffuse hair thinning is considering switching from a topical Minoxidil 10% + Finasteride 0.1% solution to Minoxidil 5% foam and oral Finasteride 0.5mg, while also addressing vitamin D deficiency and potential scalp inflammation. Users suggest using Nizoral shampoo for inflammation, considering dutasteride for better results, and maintaining vitamin D levels to protect hair follicles from DHT.

A Dutasteride Simulator predicts serum dutasteride, serum DHT, and scalp DHT levels using models from research papers. It simulates various dosing schedules to determine steady-state effects and visualizes outcomes, including hair growth-related scalp DHT suppression.

The user is experiencing increased hair shedding after one year of using oral dutasteride. They are seeking opinions on their DHT test results, which show levels below baseline.

Dr. Kang-Yell Choi's company, CK Regeon, is developing a drug called KY19382 for hair regeneration, which involves creating fine wounds to activate stem cells. The drug is in the formulation development stage, targeting markets like the US and Korea.

The user is using a combination of hair loss treatments including dutasteride, minoxidil, RU58841, low-level laser therapy, ketokonozole, supplements, Viviscal, Nutrafol, microneedling, PRP, and scalp Botox injections, but is still experiencing hair shedding and thinning. Despite being on this regimen for two years, the user's hair condition is worsening, and they are seeking advice on what else they can do.

Dr. Tsuji and Riken announced a hair cloning cure with a 98.9% success rate, expected to be released in 10 years. Users expressed hope and skepticism about the affordability and timeline of the treatment.

Finasteride reduces scalp DHT significantly even at low doses, with 0.2 mg reducing it by about 55%, but higher doses like 1 mg and 5 mg offer only marginally more reduction. Users discuss side effects, with some experiencing none and others reporting issues like low libido, and they also mention using other treatments like minoxidil and dutasteride.

PP405 (Everychem 3HP) may help with hair regrowth, with mixed user experiences. Users often combine it with minoxidil and finasteride, but there are concerns about its efficacy and side effects.

The conversation is about the best vehicle for RU58841, comparing trichosol and Garnier/Vichy Stemoxydine, avoiding propylene glycol (PG) or ethanol due to previous scalp damage. The user is also seeking sources for these products in the EU.

The conversation is about whether creatine causes hair loss in individuals who are taking finasteride or dutasteride for hair loss. Some users report experiencing hair loss when taking creatine, while others do not. There is no consensus on the issue.

The conversation is about the potential impact of RU58841 on male fertility, specifically regarding sperm concentration, total count, and motility. The user is curious about the likelihood of RU58841 reducing fertility based on its mechanism of action and comparisons to similar substances.

Increased Malassezia and Cutibacterium in the scalp microbiome are linked to higher sebum production and inflammation in androgenetic alopecia (AGA). Treatments include ciclopirox shampoo, benzoyl peroxide shampoo, clobetasol propionate, calcipotriol, minoxidil, finasteride, and dutasteride.

Tretinoin can irritate seborrheic dermatitis, but using it with a moisturizer on calm skin may help. Parallel Health's skin microbiome testing and phage therapy are suggested for persistent issues.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

Training scalp muscles to absorb more DHT is suggested as a hair loss solution, but users debate its effectiveness compared to medications like dutasteride and finasteride. Concerns about side effects of DHT blockers, such as reduced libido, are discussed, with some advocating for natural remedies like scalp massages and healthy living.

Calculating the correct dosage of vitamin D from a 60,000 IU bottle using a dropper. The user is advised to take 0.05 ml for 600 IU, but struggles with finding a suitable supplement without additional ingredients like omega 3 or calcium.

A user who has tried multiple treatments for hair loss, including oral and topical finasteride and liposomal finasteride, but experienced severe side effects in each case; the user is considering trying RU58841 or aromatise inhibitors as alternatives.

The conversation is about whether taking 0.5mg of finasteride daily is as effective as 1mg for hair regrowth and if there are long-term studies supporting the lower dose. The user is considering the lower dose to save money and reduce concerns about side effects.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.